HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Atrophic Rhinitis (Ozena)

Subscribe to New Research on Atrophic Rhinitis

A chronic inflammation in which the NASAL MUCOSA gradually changes from a functional to a non-functional lining without mucociliary clearance. It is often accompanied by degradation of the bony TURBINATES, and the foul-smelling mucus which forms a greenish crust (ozena).

Also Known As:

Ozena; Rhinitis, Atrophic; Atrophic Rhinitides; Ozenas; Rhinitides, Atrophic

Networked: 270 relevant articles (13 outcomes, 13 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Atrophic Rhinitis (Ozena)
2.	Rhinitis
3.	Sinusitis
4.	Dacryocystitis (Dacryoadenitis)
5.	Lacrimal Apparatus Diseases (Epiphora)

Experts

1.	Aktories, Klaus: 5 articles (01/2014 - 04/2009)
2.	Orth, Joachim H C: 5 articles (01/2014 - 04/2009)
3.	Horiguchi, Yasuhiko: 3 articles (01/2015 - 01/2010)
4.	Jiang, Hu-Lin: 3 articles (06/2008 - 03/2004)
5.	Yoo, Han Sang: 3 articles (06/2008 - 03/2002)
6.	Fukui-Miyazaki, Aya: 2 articles (01/2015 - 01/2010)
7.	Byeon, Hoyeon: 2 articles (10/2014 - 09/2014)
8.	Lee, John Hwa: 2 articles (10/2014 - 09/2014)
9.	Hur, Jin: 2 articles (10/2014 - 09/2014)
10.	Huang, Chienjin: 2 articles (05/2009 - 01/2006)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Atrophic Rhinitis:

1.	VaccinesIBA 06/01/1992 - "Use of rats to compare atrophic rhinitis vaccines for protection against effects of heat-labile protein toxin produced by Pasteurella multocida serogroup D." 10/01/1985 - "A mouse protection test utilizing a lethal intraperitoneal challenge failed to monitor the efficacy of vaccines for protection against atrophic rhinitis." 03/15/2002 - "Evaluation of vaccines for atrophic rhinitis--a comparison of three challenge models." 03/01/2002 - "In particular, laying rates of hens injected with vaccines against atrophic rhinitis were increased up to 84% by injecting a vaccine composed of only the DNTs of B. " 01/01/1996 - "Serological potency testing of vaccines against progressive atrophic rhinitis."
2.	Bacterial VaccinesIBA 01/01/1997 - "multocida serotype D bacterin-toxoid is effective against atrophic rhinitis caused by toxigenic P. " 01/01/1979 - "The efficacy of a Bordetella bronchiseptica bacterin was evaluated in 2 commercial swine herds affected with mild and severe enzootic atrophic rhinitis (AR). " 01/01/1979 - "Efficacy of Bordetella bronchiseptica bacterin in controlling enzootic atrophic rhinitis in swine." 05/14/2009 - "multocida whole-cell bacterin (rsPMT-PM) was evaluated in field studies for prevention and control of progressive atrophic rhinitis (PAR) of swine at 15 conventional farrow-to-finish farms. " 07/01/1977 - "Control of atrophic rhinitis with a Bordetella bronchiseptica bacterin."
3.	Pasteurella multocida toxinIBA 01/01/2014 - "Pasteurella multocida toxin (PMT) induces degradation of nasal turbinate bones, leading to the syndrome of atrophic rhinitis. " 01/01/2014 - "Pasteurella multocida toxin (PMT) induces atrophic rhinitis in animals, which is characterized by a degradation of nasal turbinate bones, indicating an effect of the toxin on bone cells such as osteoblasts and osteoclasts. " 01/01/2012 - "Pasteurella multocida toxin (PMT) is the causative agent of progressive atrophic rhinitis in swine. " 12/01/1996 - "Atrophic rhinitis is characterized by a lack of an immune response towards Pasteurella multocida toxin (Pm-T). " 06/01/1995 - "Effects of atrophic rhinitis induced by Pasteurella multocida toxin on heat production and activity of pigs kept under different climatic conditions."
4.	IronIBA 03/01/1975 - "Good results of iron therapy obtained in ozena patients with significantly lowered serum iron level encouraged studies on the pathogenesis of the disease. " 01/01/1993 - "A case of TO coexisting with ozena and iron deficiency anaemia was described." 05/01/1987 - "Iron-deficiency in atrophic rhinitis & scleroma." 01/01/1974 - "[Treatment of ozena with iron preparations]." 12/01/1968 - "[Iron metabolism in ozena]."
5.	AntigensIBA 10/01/2014 - "Immunologic study and optimization of Salmonella delivery strains expressing adhesin and toxin antigens for protection against progressive atrophic rhinitis in a murine model." 10/01/2014 - "Mice were intranasally inoculated at various times to optimize the vaccination strategy with a new live candidate vaccine expressing the antigens CP39, FimA, PtfA, and ToxA of Pasteurella multocida and F1P2 of Bordetella bronchiseptica in an attenuated live Salmonella system to protect against progressive atrophic rhinitis (PAR). " 09/03/2014 - "Generation of an attenuated Salmonella-delivery strains expressing adhesin and toxin antigens for progressive atrophic rhinitis, and evaluation of its immune responses in a murine model." 01/01/1974 - "Lesions of experimental swine atrophic rhinitis and Alcaligenes bronchisepticus antigen detected by fluorescent antibody technique." 09/03/2014 - "An expression/secretion plasmid containing genes encoding the FimA, CP39, PtfA, ToxA and F1P2 antigens associated with porcine pneumonic pasteurellosis and progressive atrophic rhinitis (PAR) was constructed and harbored in an attenuated Salmonella Typhimurium, which was used as the vaccine candidate. "
6.	Rifampin (Rifampicin)FDA LinkGeneric 10/01/2008 - "The aim of this randomized control trial, performed at a tertiary referral hospital, was to compare the therapeutic effectiveness of two novel treatment modalities, oral rifampicin and submucosal placentrex injection, in randomly selected patients of primary atrophic rhinitis regarding objective, subjective and histopathological improvement. "
7.	HeliumIBA 01/01/2012 - "The method for the treatment of atrophic rhinitis is described; it includes the application of helium-neon laser radiation in combination with the administration of the purified preparation of liquid polyvalent Klebsiella bacteriophage. " 01/01/2012 - "[The application of helium-neon laser radiation for the combined treatment of the patients with atrophic rhinitis]." 01/01/2012 - "The objective of the present study was to improve the efficacy of the treatment of the patients presenting with atrophic rhinitis (ozena) of the upper respiratory tract by the application of helium-neon laser radiation. "
8.	Niacin (Nicotinic Acid)FDA LinkGeneric 07/01/1950 - "[Therapeutic efficacy of nicotinic acid in simple atrophic rhinitis and in ozenous atrophic rhinitis]." 01/01/1955 - "[Local treatment of atrophic rhinitis with nicotinic acid derivatives]." 07/01/1950 - "[Nasal vasomotor modifications from nicotinic acid in simple atrophic rhinitis and in ozenous atrophic rhinitis]." 03/01/1953 - "Effect of a combined administration of aureomycin and nicotinic acid in ozena." 07/01/1965 - "[Use of streptomycin, nicotinic acid and vitamin "A" in ozena]."
9.	Monoclonal AntibodiesIBA 01/01/1991 - "Western blotting with monoclonal antibodies to toxin from a P multocida isolate causing atrophic rhinitis in pigs revealed the toxin that induces pleuritis and pneumonia in rabbits to be the same or a closely related toxin." 07/01/1989 - "Protection against progressive atrophic rhinitis by vaccination with Pasteurella multocida toxin purified by monoclonal antibodies."
10.	Imipramine (Janimine)FDA LinkGeneric 01/01/1960 - "[Ozena and nervous depression improved by imipramine]."

Therapies and Procedures

1.	Lasers (Laser) 05/01/1986 - "[Low-energy laser radiation in the combined therapy of ozena patients]." 01/01/1994 - "Using a laser Doppler flowmeter (He-Ne Laser equipment PF2 type), we measured the nasal mucosa blood flow (NMBF) in a group of healthy young subjects 108 (18-25 years) and three types of chronic rhinitis 89 (chronic rhinitis 15, allergic rhinitis 44, atrophic rhinitis 30). " 07/01/2004 - "A prospective study on 27 cases of chronic dacryocystitis was done to see the outcome of management by End-DCR in Indian population and to look for advantages or disadvantages over Ext-DCR from available datas in literature All cases were diagnosed clinically by regurgitation test and lacrimal syringing In selected cases Jones dye test, dacryocystogram and CT scan of nose and paranasal sinuses (PNS) was done to confirm the site of obstruction and find out the cause Cases having hyperlacrumation due to other causes and epiphora due to presaccal stenosis were excluded Cause of NLD obstruction was atrophic rhinitis (4 cases), chronic sinusitis (4 cases), enlarged agger nasi cells (4 cases), faciomaxillary injury (1 case) and unknown in rest of cases All cases were treated by End-DCR under local anaesthesia Concommitent nose and PNS surgeries were done in selected cases where it was supposed to be the cause Average follow-up was from 3 months to 1 year Primary success rate was 92 6% and after revision in two cases final success was 96% Success rate was 100% in cases of atrophie rhinitis Major complication was not found in any case Our result of End-DCR was as good as Ext-DCR Our results of End-DCR are better than those who had used lacnmal stent, lasers, microdebriders, dacryoendoscope and electrocautery It was finally concluded that end-DCR by using simple instruments is a safe and effective procedure." 01/01/2012 - "The method for the treatment of atrophic rhinitis is described; it includes the application of helium-neon laser radiation in combination with the administration of the purified preparation of liquid polyvalent Klebsiella bacteriophage. " 01/01/2012 - "[The application of helium-neon laser radiation for the combined treatment of the patients with atrophic rhinitis]."
2.	Stents 06/01/2011 - "A new technique for nasal stent fabrication for atrophic rhinitis: a clinical report." 07/01/2004 - "A prospective study on 27 cases of chronic dacryocystitis was done to see the outcome of management by End-DCR in Indian population and to look for advantages or disadvantages over Ext-DCR from available datas in literature All cases were diagnosed clinically by regurgitation test and lacrimal syringing In selected cases Jones dye test, dacryocystogram and CT scan of nose and paranasal sinuses (PNS) was done to confirm the site of obstruction and find out the cause Cases having hyperlacrumation due to other causes and epiphora due to presaccal stenosis were excluded Cause of NLD obstruction was atrophic rhinitis (4 cases), chronic sinusitis (4 cases), enlarged agger nasi cells (4 cases), faciomaxillary injury (1 case) and unknown in rest of cases All cases were treated by End-DCR under local anaesthesia Concommitent nose and PNS surgeries were done in selected cases where it was supposed to be the cause Average follow-up was from 3 months to 1 year Primary success rate was 92 6% and after revision in two cases final success was 96% Success rate was 100% in cases of atrophie rhinitis Major complication was not found in any case Our result of End-DCR was as good as Ext-DCR Our results of End-DCR are better than those who had used lacnmal stent, lasers, microdebriders, dacryoendoscope and electrocautery It was finally concluded that end-DCR by using simple instruments is a safe and effective procedure."
3.	Electrocoagulation (Electrocautery) 07/01/2004 - "A prospective study on 27 cases of chronic dacryocystitis was done to see the outcome of management by End-DCR in Indian population and to look for advantages or disadvantages over Ext-DCR from available datas in literature All cases were diagnosed clinically by regurgitation test and lacrimal syringing In selected cases Jones dye test, dacryocystogram and CT scan of nose and paranasal sinuses (PNS) was done to confirm the site of obstruction and find out the cause Cases having hyperlacrumation due to other causes and epiphora due to presaccal stenosis were excluded Cause of NLD obstruction was atrophic rhinitis (4 cases), chronic sinusitis (4 cases), enlarged agger nasi cells (4 cases), faciomaxillary injury (1 case) and unknown in rest of cases All cases were treated by End-DCR under local anaesthesia Concommitent nose and PNS surgeries were done in selected cases where it was supposed to be the cause Average follow-up was from 3 months to 1 year Primary success rate was 92 6% and after revision in two cases final success was 96% Success rate was 100% in cases of atrophie rhinitis Major complication was not found in any case Our result of End-DCR was as good as Ext-DCR Our results of End-DCR are better than those who had used lacnmal stent, lasers, microdebriders, dacryoendoscope and electrocautery It was finally concluded that end-DCR by using simple instruments is a safe and effective procedure."
4.	Injections 03/01/2011 - "Three patients suffering from ENS and atrophic rhinitis underwent trial treatment consisting of submucosal injections of HA preparations into the inferior nasal concha and under the mucous membrane of the septum. " 06/01/1966 - "The treatment of atrophic rhinitis with injectable silicone." 07/01/1964 - "SURGICAL TREATMENT OF ATROPHIC RHINITIS WITH INJECTABLE SILICONE. "
5.	Intranasal Administration 06/01/2008 - "Therefore, the mucosal and systemic immune responses induced in the current study would seem to indicate that the intranasal administration of BBD-CMs may be an effective vaccine against atrophic rhinitis in pigs." 04/01/1987 - "Prevention of atrophic rhinitis in piglets by means of intranasal administration of a live non-AR-pathogenic Bordetella bronchiseptica vaccine." 01/01/1994 - "Intranasal administration of Pasteurella multocida toxin in a challenge-exposure model used to induce subclinical signs of atrophic rhinitis in pigs."